Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading to replication-induced DNA damage that requires BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lloyd, Rebecca L., Wijnhoven, Paul W. G., Ramos-Montoya, Antonio, Wilson, Zena, Illuzzi, Giuditta, Falenta, Katarzyna, Jones, Gemma N., James, Neil, Chabbert, Christophe D., Stott, Jonathan, Dean, Emma, Lau, Alan, Young, Lucy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299845/
https://www.ncbi.nlm.nih.gov/pubmed/32444694
http://dx.doi.org/10.1038/s41388-020-1328-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299845/
https://www.ncbi.nlm.nih.gov/pubmed/32444694
http://dx.doi.org/10.1038/s41388-020-1328-y

Ejemplares similares